

yyyy

y



PERÚ

Ministerio  
de Salud

Instituto Nacional  
de Salud

"Decenio de la Igualdad de Oportunidades para Mujeres y Hombres"  
"Año de la Esperanza y el Fortalecimiento de la Democracia"

## COMMUNICATION No. 002-2026-DIIS/INS

Publication close: 04/10/2026

About the notification of reports and deviations in clinical trials through the REPEC platform

The Subdirection of Clinical Trials (SUDEC) of the Directorate of Research and Innovation in Health (DIIS) of the National Health Institute (INS), within the framework of which it was established in the Regulation of Clinical Trials of Peru, approved by Supreme Decree N°021-2017-SA, communicates to sponsors, contract research organizations, researchers and other actors linked to clinical research the following:

- In accordance with articles 40.n), 104 and 105 of the REC, the Sponsor is responsible for notifying, by own account through OIC, progress reports, final reports and results reports, as well as deviations occurring in clinical trials.

### POPOP ANNOUNCEMENT

- Notification of reports and deviations will be managed through the platform of the Peruvian Registry of Clinical Trials (REPEC) and formalized through the Digital Parties Table (MPD) of the INS.
- Therefore, those responsible are encouraged to make these notifications through the REPEC and carry out the corresponding follow-up, whenever the results of the evaluation of the same and their subsequent acceptance or rejection, as well as possible clarification requests, will be communicated exclusively through this platform.

Subdirection of Clinical Trials  
Directorate of Research and Innovation in Health – DIIS  
National Institute of Health